Obinutuzumab (RO5072759; GA101)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Obinutuzumab (RO5072759; GA101), covering 2014-04-24 to 2014-04-24. Get the full timeline:
Most recent: Clinical Trial Update: A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE) [Phase 2]